5 Must-Knows Before Tuesday’s Market Opens

Good morning. Investors are gearing up for a potentially active trading session as key economic and corporate developments unfold. Amidst a backdrop of market anticipation, several significant events are poised to shape the day’s narrative.

Here are five critical insights to navigate the trading landscape today:

Apple has initiated a significant leadership transition with the announcement that John Ternus, currently heading the company’s hardware division, will assume the role of CEO in September, succeeding Tim Cook. Cook is slated to transition to the position of Executive Chairman. This succession plan, while surprising to some market participants, is being viewed by investors as a strategic move towards continuity, particularly given Ternus’s deep-seated expertise in hardware development. This background is crucial as Apple navigates the increasingly competitive landscape of artificial intelligence, an area where analysts perceive the company as needing to accelerate its progress against its megacap rivals. The ability of Ternus to steer Apple’s AI strategy and integrate advanced AI capabilities across its product ecosystem will be a defining challenge and a key determinant of the company’s future growth trajectory. Apple’s stock, which had seen a modest rise in 2026, experienced a slight dip in after-hours trading, underscoring the market’s immediate reaction to this pivotal leadership change. Since taking the helm in 2011, Cook has overseen an unprecedented period of growth for Apple, with its stock appreciating by over 1,930%.

In Washington, the focus sharpens on Kevin Warsh’s confirmation hearing before the Senate Banking Committee today, as he is President Trump’s nominee to succeed Jerome Powell as the Chair of the Federal Reserve. Warsh’s prepared remarks signal an emphasis on maintaining the Federal Reserve’s independence from political pressures, though with subtle caveats. He stressed that the central bank must adhere to its mandate and refrain from venturing into fiscal or social policy domains, asserting that “Fed independence is largely up to the Fed.” This positions Warsh to navigate a delicate balance between accommodating the administration’s desire for lower interest rates and demonstrating his commitment to an impartial monetary policy framework. His confirmation process is likely to involve scrutiny over his extensive ties to the technology sector and his personal wealth. Furthermore, Senator Thom Tillis has indicated his opposition to Warsh’s confirmation pending the resolution of the ongoing criminal investigation into former Chair Powell, adding another layer of complexity to the proceedings.

Yesterday marked a halt to the Nasdaq Composite’s longest winning streak since 1992, with broader market indices also experiencing a retreat. The S&P 500 saw its first negative session in six trading days. These declines coincided with heightened geopolitical tensions, as President Trump issued strong rhetoric regarding Iran, introducing a degree of market uncertainty. Despite this, small-cap stocks demonstrated resilience, with the Russell 2000 reaching new intraday and closing highs. This divergence suggests a potential rotation within the market, with investors seeking opportunities in smaller, more agile companies amidst broader economic and geopolitical considerations.

UnitedHealth Group reported robust first-quarter results, surpassing analyst expectations for both revenue and earnings, and consequently raised its full-year earnings guidance. A significant factor contributing to this strong performance was the company’s improved management of medical costs, which have been a persistent challenge in the healthcare sector. The medical benefit ratio, a key indicator of an insurer’s profitability, showed improvement in the first quarter, suggesting enhanced efficiency in claims processing and cost containment. This positive momentum follows a favorable development earlier in April, with the government confirming a higher-than-anticipated payment rate for Medicare Advantage plans for 2027. As of Monday’s close, UnitedHealth Group’s stock had already surged by nearly 20% in April, reflecting strong investor confidence in its operational resilience and strategic positioning within the evolving healthcare landscape.

The burgeoning field of psychedelic research has received a significant boost following President Trump’s executive order aimed at accelerating studies and access to compounds like psilocybin, MDMA, and ibogaine. This development has sparked considerable investor enthusiasm, with shares of companies at the forefront of this research experiencing substantial gains. Compass Pathways saw its stock surge by 42% yesterday, marking its best trading day on record, while Atai Life Sciences climbed over 21%, its strongest performance since July. The key question now is whether these novel therapeutics will navigate the complex regulatory pathways with greater efficiency than has been seen with cannabis. Legal experts note that the governmental review process for such substances has historically been protracted and challenging, presenting a significant hurdle for widespread adoption and commercialization. The success of these initiatives will hinge on the ability to streamline regulatory frameworks and foster further scientific validation.

U.S. importers are poised to receive substantial tariff refunds, potentially exceeding $160 billion, following a Supreme Court ruling that invalidated many of President Trump’s tariffs earlier this year. According to analysis from Citi, major retail corporations are expected to benefit significantly from these reimbursements. This development could provide a notable boost to the bottom lines of these companies and potentially influence consumer pricing strategies.